Haemonetics Co. (NYSE:HAE) Shares Sold by Royce & Associates LP

Royce & Associates LP cut its position in Haemonetics Co. (NYSE:HAE) by 4.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,153,268 shares of the medical instruments supplier’s stock after selling 57,278 shares during the quarter. Haemonetics accounts for 0.8% of Royce & Associates LP’s investment portfolio, making the stock its 7th largest holding. Royce & Associates LP’s holdings in Haemonetics were worth $90,047,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. FMR LLC boosted its holdings in shares of Haemonetics by 206.3% in the 3rd quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock worth $62,257,000 after acquiring an additional 521,640 shares in the last quarter. Wellington Management Group LLP boosted its stake in Haemonetics by 9.5% in the third quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock worth $337,722,000 after purchasing an additional 363,702 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in Haemonetics by 29.5% in the third quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier’s stock worth $88,433,000 after purchasing an additional 250,833 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Haemonetics in the fourth quarter valued at $19,002,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Haemonetics by 439.9% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 220,453 shares of the medical instruments supplier’s stock valued at $17,720,000 after buying an additional 179,621 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Haemonetics Stock Performance

HAE stock opened at $65.76 on Friday. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a twelve month low of $58.80 and a twelve month high of $97.97. The business’s fifty day moving average is $68.61 and its 200-day moving average is $75.41. The company has a market cap of $3.30 billion, a P/E ratio of 25.89, a price-to-earnings-growth ratio of 1.11 and a beta of 0.43.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Equities research analysts forecast that Haemonetics Co. will post 4.55 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on HAE. Needham & Company LLC decreased their price objective on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating on the stock in a report on Friday, February 7th. JPMorgan Chase & Co. assumed coverage on shares of Haemonetics in a research note on Friday, December 6th. They set an “overweight” rating and a $116.00 price target on the stock. Raymond James restated a “strong-buy” rating and issued a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. Finally, JMP Securities dropped their target price on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research report on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $101.67.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.